ClinicalTrials.gg
CompletedNCT05195216Updated Jan 18, 2022

Psychosocial Factors and Quality of Life in the Effect of Fear of COVID-19 With Cystic Fibrosis

An observational study in Cystic Fibrosis, sponsored by Elif Kabasakal. Completed at 1 site in Turkey. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-18.

Sponsored by Elif Kabasakal · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
128
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Cystic Fibrosis with a site in Turkey — 4 open to participants now, 4 under way, none of them phase 3. Cystic Fibrosis · Turkey.

Enrollment
Largest of 27
128 · median 50
Started
2021
with 8 others
Observational
27 of 49
3 open now
Registered
24th of 49
by date
Lead sponsor
1 of 49
Elif Kabasakal

Among the 49 studies in Cystic Fibrosis with a site in Turkey, this one has the largest enrollment of the 27 observational ones that give a count, is one of 9 that started in 2021, is one of 27 observational ones, and was the 24th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 49 studies in Cystic Fibrosis with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Cystic Fibrosis with a site in Turkey, or all of them as a file.
02

Study summary

The purpose of this study; The COVID-19 pandemic is to investigate the effects of COVID-19 fear levels of patients with cystic fibrosis on the psychosocial and quality of life levels of individuals.

Read the detailed description

After individuals were informed about the study, it was administered to individuals who gave written informed consent.This study was carried out on individuals with cystic fibrosis and healthy individuals who meet the eligibility requirements, through online forms.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

64 individuals with cystic fibrosis and 70 healthy individuals participated in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be 16 years of age or older
  • Having been diagnosed with Cystic Fibrosis
  • Volunteering to participate in the research

Exclusion criteria

Exclusion Criteria:

  • Being mentally incapable of successfully applying the scales to be applied for evaluation purposes
  • Being treated with sedative and antiepileptic drugs
  • Pregnancy
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
128 participants (actual)
Patient registry
No

Groups and cohorts

  • individuals with cystic fibrosis

    Behavioral: Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form

  • healthy individuals

    Behavioral: Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form

Interventions

  • BehavioralSurvey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form

    Online questionnaires were administered to individuals.

06

What researchers measure

Primary outcomes

  1. fear of covid-19

    COVID-19 Fear Scale: This scale is a one-dimensional instrument consisting of seven items with robust psychometric properties that measure fear of COVID-19. It has a 5-point Likert-type rating system (1: Strongly disagree, 5: Strongly agree). It is reliable and valid in assessing fear of COVID-19 among the general population. Turkish validity and reliability of the scale were ensured.

    Time frame: November- December/2021

Secondary outcomes

  1. psychosocial factors

    Hospital Anxiety and Depression Scale (HADS): The scale consists of 14 items. 7 of these items measure anxiety and 7 of them measure depression symptoms. The items in the scale are evaluated with a 4-point Likert scale and are based on a scoring system between 0-3.

    Time frame: November-December/2021November-December/2021

Other outcomes

  1. quality of life assessment

    It is an internationally comparable assessment tool developed by the World Health Organization. The scale evaluates the level of quality of life. The scale consists of 26 items. The Turkish version of WHOQOL-Bref consists of 27 items. Question 27 has been added to the Turkish version of the scale as a national environmental field and is used only in national studies. The scale includes the areas of physical health, psychological health, social relations, environment and national environment. It has a 5-point likert-type rating system. The score of each area is important on its own. Higher scores in each area indicate better quality of life. The first two questions of the quality of life scale are not included in the scoring and are evaluated separately. The number of questions, which was 26 in the original of the scale, is used as 27 in the Turkish version.

    Time frame: November-December/2021November-December/2021

07

Study locations

1 site
  • Elif Kabasakal
    Istanbul, İ̇stanbul 34734, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Jan 18, 2022
StartActual
Nov 20, 2021
Primary completionActual
Nov 30, 2021
CompletionActual
Dec 25, 2021
Last update
Jan 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05195216
Lead sponsor
Elif Kabasakal
Responsible party
Elif Kabasakal (ekabasakal, Medipol University) — Sponsor-investigator
First posted
Jan 18, 2022
Start date
Nov 20, 2021
Primary completion
Nov 30, 2021
Completion
Dec 25, 2021
Last update
Jan 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion